Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants

Category	Detail
Condition
Key Mechanisms	SGLT2 inhibitors have been shown to prevent hospitalization for HF, as evidenced by the DECLARE-TIMI 58 trial.
Target Population
Care Setting

Dapagliflozin reduced hospitalization for HF by 32% in the overall cohort (DECLARE-TIMI 58 trial).
Carriers of CMP variants had an 82% reduction in incident HF with dapagliflozin (DECLARE-TIMI 58 trial).
The incidence of HF in carriers decreased from 16.1% to 3.1% with dapagliflozin treatment (DECLARE-TIMI 58 trial).
Carriers of CMP variants had an over eightfold increased risk of HF compared to noncarriers (DECLARE-TIMI 58 trial).
The number needed to treat with dapagliflozin for carriers was 7.7 over 4.2 years (DECLARE-TIMI 58 trial).

Consider SGLT2 inhibitors for patients with CMP variants to reduce HF risk, as per European and American guidelines.

Individuals with CMP-associated genetic variants.

Dapagliflozin shows significant efficacy in reducing HF incidence in carriers of CMP variants.

Utilize genetic testing for patients with a family history of cardiomyopathy, as recommended in European and American guidelines.
Monitor NT-proBNP levels in patients with CMP variants, based on clinical practice guidelines.
Consider early intervention with SGLT2 inhibitors in asymptomatic carriers, if supported by clinical evidence.

Clinical Scorecard: Impact of SGLT2 Inhibitors on the Development of Heart Failure in Individuals with Genetic Variants Linked to Cardiomyopathy